dc.contributor.author | Jerjes-Sánchez, C | en_US |
dc.contributor.author | Rodriguez, D | en_US |
dc.contributor.author | Farjat, AE | en_US |
dc.contributor.author | Kayani, G | en_US |
dc.contributor.author | MacCallum, P | en_US |
dc.contributor.author | Lopes, RD | en_US |
dc.contributor.author | Turpie, AGG | en_US |
dc.contributor.author | Weitz, JI | en_US |
dc.contributor.author | Haas, S | en_US |
dc.contributor.author | Ageno, W | en_US |
dc.contributor.author | Goto, S | en_US |
dc.contributor.author | Goldhaber, SZ | en_US |
dc.contributor.author | Angchaisuksiri, P | en_US |
dc.contributor.author | Nielsen, JD | en_US |
dc.contributor.author | Schellong, S | en_US |
dc.contributor.author | Bounameaux, H | en_US |
dc.contributor.author | Mantovani, LG | en_US |
dc.contributor.author | Prandoni, P | en_US |
dc.contributor.author | Kakkar, AK | en_US |
dc.contributor.author | GARFIELD-VTE investigators | en_US |
dc.date.accessioned | 2021-09-20T11:40:28Z | |
dc.date.available | 2020-11-30 | en_US |
dc.date.issued | 2021-01 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/74144 | |
dc.description.abstract | Introduction The risk of venous thromboembolism (VTE) increases during pregnancy and the puerperium such that VTE is a leading cause of maternal mortality. Methods We describe the clinical characteristics, diagnostic strategies, treatment patterns, and outcomes of women with pregnancy-associated VTE (PA-VTE) enrolled in the Global Anticoagulant Registry in the FIELD (GARFIELD)-VTE. Women of childbearing age (<45 years) were stratified into those with PA-VTE ( n = 183), which included pregnant patients and those within the puerperium, and those with nonpregnancy associated VTE (NPA-VTE; n = 1,187). Patients with PA-VTE were not stratified based upon the stage of pregnancy or puerperium. Results Women with PA-VTE were younger (30.5 vs. 34.8 years), less likely to have pulmonary embolism (PE) (19.7 vs. 32.3%) and more likely to have left-sided deep vein thrombosis (DVT) (73.9 vs. 54.8%) compared with those with NPA-VTE. The most common risk factors in PA-VTE patients were hospitalization (10.4%), previous surgery (10.4%), and family history of VTE (9.3%). DVT was typically diagnosed by compression ultrasonography (98.7%) and PE by chest computed tomography (75.0%). PA-VTE patients more often received parenteral (43.2 vs. 15.1%) or vitamin K antagonists (VKA) (9.3 vs. 7.6%) therapy alone. NPA-VTE patients more often received a DOAC alone (30.2 vs. 13.7%). The risk (hazard ratio [95% confidence interval]) of all-cause mortality (0.59 [0.18-1.98]), recurrent VTE (0.82 [0.34-1.94]), and major bleeding (1.13 [0.33-3.90]) were comparable between PA-VTE and NPA-VTE patients. Uterine bleeding was the most common complication in both groups. Conclusion VKAs or DOACs are widely used for treatment of PA-VTE despite limited evidence for their use in this population. Rates of clinical outcomes were comparable between groups. | en_US |
dc.format.extent | e24 - e34 | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | TH Open | en_US |
dc.rights | Creative Commons Attribution License | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | deep vein thrombosis | en_US |
dc.subject | pregnancy | en_US |
dc.subject | pulmonary embolism | en_US |
dc.subject | registry | en_US |
dc.subject | venous thromboembolism | en_US |
dc.title | Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. | en_US |
dc.type | Article | |
dc.rights.holder | © 2021. The Author(s) | |
dc.identifier.doi | 10.1055/s-0040-1722611 | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/33532693 | en_US |
pubs.issue | 1 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published online | en_US |
pubs.volume | 5 | en_US |
dcterms.dateAccepted | 2020-11-30 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |